Lyra Therapeutics, Inc.
LYRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $671,975 | $13,033,452 | $4,747,003 | $2,830,970 |
| - Cash | $40,577 | $22,353 | $32,550 | $45,747 |
| + Debt | $34,380 | $26,881 | $4,177 | $1,453 |
| Enterprise Value | $665,778 | $13,037,980 | $4,718,630 | $2,786,676 |
| Revenue | $1,534 | $1,558 | $1,363 | $285 |
| % Growth | -1.5% | 14.3% | 378.2% | – |
| Gross Profit | $1,534 | $1,558 | $1,363 | -$29,409 |
| % Margin | 100% | 100% | 100% | -10,318.9% |
| EBITDA | -$60,262 | -$65,250 | -$53,923 | -$42,614 |
| % Margin | -3,928.4% | -4,188.1% | -3,956.2% | -14,952.3% |
| Net Income | -$93,435 | -$62,680 | -$55,278 | -$43,513 |
| % Margin | -6,090.9% | -4,023.1% | -4,055.6% | -15,267.7% |
| EPS Diluted | -1.43 | -1.26 | -1.83 | -3.35 |
| % Growth | -13.5% | 31.1% | 45.4% | – |
| Operating Cash Flow | -$70,011 | -$63,304 | -$43,385 | -$25,820 |
| Capital Expenditures | -$2,338 | -$1,047 | -$164 | -$3,385 |
| Free Cash Flow | -$72,349 | -$64,351 | -$43,549 | -$29,205 |